| Literature DB >> 28286734 |
Motonori Tsuji1, Koichi Shudo2, Hiroyuki Kagechika3.
Abstract
Understanding and identifying the receptor subtype selectivity of a ligand is an important issue in the field of drug discovery. Using a combination of classical molecular mechanics and quantum mechanical calculations, this report assesses the receptor subtype selectivity for the human retinoid X receptor (hRXR) and retinoic acid receptor (hRAR) ligand-binding domains (LBDs) complexed with retinoid ligands. The calculated energies show good correlation with the experimentally reported binding affinities. The technique proposed here is a promising method as it reveals the origin of the receptor subtype selectivity of selective ligands.Entities:
Keywords: drug design; quantum mechanics; receptor subtype selectivity; retinoic acid receptors; retinoid X receptors; retinoids
Year: 2017 PMID: 28286734 PMCID: PMC5337894 DOI: 10.1002/2211-5463.12188
Source DB: PubMed Journal: FEBS Open Bio ISSN: 2211-5463 Impact factor: 2.693
Figure 1Naturally occurring (ATRA and 9cRA) and synthetic retinoids (Am80 and LGD1069).
Experimental ΔG bind values 15 and calculated energies of naturally occurring and synthetic retinoids
| Receptor | Ligand | Δ | ONIOM (MP2/6‐31G: AMBER) Δ | FMO (MP2/6‐31G) IFIE (kcal·mol−1) | Docking IE (kcal·mol−1) |
|---|---|---|---|---|---|
| hRXRα (PDB ID: | ATRA | −8.81 | −98.70 | −208.34 | −81.83 |
| 9cRA | −10.76 | −117.92 | −221.14 | −94.41 | |
| Am80 | nb | – | – | nh | |
| LGD1069 | −10.59 | −106.70 | −218.55 | −87.55 | |
| hRXRβ (PDB ID: | ATRA | −9.87 | −107.35 | −231.73 | −89.36 |
| 9cRA | −11.44 | −130.52 | −238.15 | −97.08 | |
| Am80 | nb | – | – | nh | |
| LGD1069 | −11.18 | −127.32 | −238.15 | −87.77 | |
| hRXRγ (Model) | ATRA | −9.40 | −73.75 | −149.30 | −78.60 |
| 9cRA | −10.81 | −72.57 | −149.11 | −83.76 | |
| Am80 | nb | – | – | nh | |
| LGD1069 | −10.98 | −61.86 | −154.81 | −72.02 | |
| hRARα (PDB ID: | ATRA | −11.52 | −88.37 | −209.22 | −95.94 |
| 9cRA | nd | −84.31 | −198.00 | −94.03 | |
| Am80 | −11.12 | −92.90 | −202.27 | −101.63 | |
| LGD1069 | −9.16 | −76.64 | −195.29 | −84.03 | |
| hRARβ (PDB ID: | ATRA | −11.39 | −137.46 | −228.61 | −107.72 |
| 9cRA | nd | −131.73 | −223.41 | −112.03 | |
| Am80 | −10.22 | −139.99 | −223.06 | −122.27 | |
| LGD1069 | −9.92 | −124.27 | −204.95 | −89.47 | |
| hRARγ (PDB ID: | ATRA | −14.13 | −147.43 | −221.82 | −108.99 |
| 9cRA | −12.23 | −137.60 | −213.63 | −103.19 | |
| Am80 | nb | – | – | nh | |
| LGD1069 | −9.35 | −124.97 | −190.48 | −60.91 |
nb, does not bind; nd, no data available; nh, no hit.
Ref. 15.
Figure 2Correlations between ΔG bind(exp) 15 and ΔG bind(calc) (circles), IFIE (triangles), and interaction energies of the most stable complex obtained from the docking simulations (squares) for the binding of the α, β, and γ subtypes of hRXR and hRAR LBDs with ATRA, 9cRA, Am80, and LGD1069. Left‐hand side shows the correlation diagram for all six receptors. Right‐hand side shows the correlation diagram for hRXRα, hRXRβ, hRARβ, and hRARγ LBDs. At the top, red color represents the correlation for ATRA and 9cRA.
Amino acid residues of the ligand‐binding sites of hRXRs and hRARs
| hRXRα | hRXRβ | hRXRγ | hRARα | hRARβ | hRARγ |
|---|---|---|---|---|---|
| F199 | F199 | F201 | |||
| I268 | I339 | I269 | F228 | F228 | F230 |
| A271 | A342 | A272 | L231 | L231 | L233 |
| A272 | A343 | A273 |
|
|
|
| Q275 | Q346 | Q276 | C235 | C235 | C237 |
| N306 | N377 | N307 | L266 | L266 | L268 |
| L309 | L380 | L310 | L269 | L269 | L271 |
| I310 | I381 | I311 |
|
|
|
| S312 | S383 | S313 | R272 | R272 | R274 |
| F313 | F384 | F314 | I273 | I273 | I275 |
| R316 | R387 | R317 | R276 | R276 | R278 |
| L326 | L397 | L327 | F286 | F286 | F288 |
| A327 | A398 | A328 | S287 | S287 | S289 |
| V342 | V413 | V343 | F302 | F302 | F304 |
| I345 | I416 | I346 | L305 | L305 | L307 |
| C432 | C503 | C433 | G391 | G391 | G393 |
| H435 | H506 | H436 | R394 | R394 | R396 |
| L436 | L507 | L437 |
|
|
|
| F439 | F510 | F440 | L398 | L398 | L400 |
| M413 | M413 | M415 | |||
| L414 | L414 | L416 |
Residues that differ between the subtypes are represented in bold face. The sequence alignments of hRXR and hRAR LBDs have been reported in Ref. 1.
Figure 3Three‐layer ONIOM (B3LYP/6‐31G*:AM1:AMBER)‐optimized structures of the most stable complex obtained from the biomacromolecule‐rigid and ligand‐flexible docking simulations for the binding of the α, β, and γ subtypes of hRXR and hRAR LBDs with ATRA, 9cRA, Am80, and LGD1069. The structures of ATRA and 9cRA were modified (or further optimized) from the previous structures 2, although these docking poses were maintained.